Company News

Share this article:

IMS Health put itself up for sale, according to several reports citing people familiar with the matter. According to a Wall Street Journal report, the offers – from TPG, Silver Lake and BC Partners – are expected to give IMS stockholders a 30% premium on their shares, valuing the company at approximately $3.5 billion. Shares were up 21.6% - to $17.84 – following the WSJ report yesterday afternoon.

Bristol-Myers Squibb will cut roughly 25% of its Abilify sales force, according to a Bloomberg report. The cuts are a result of Otsuka Pharmaceuticals, a partner on the antipsychotic drug, taking over more of the marketing duties on Abilify, according to the report.  


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.